Therapeutics, Inc. (NASDAQ: OSIR), announced today that the
manuscript from its multi-center (n=20), randomized, controlled clinical
trial comparing the safety and effectiveness of Grafix® to control in
patients with chronic diabetic foot ulcers (DFUs), which was accepted
for publication in the International Wound Journal , is now
and will also be in an upcoming issue.
for Grafix® Manuscript from Osiris’ Multi-center, Randomized, Controlled Clinical Trial Available Electronically in Peer-Reviewed Journal investment picks